• Neurizon signs a five-year supply agreement with Elanco Animal Health
• Agreement provides long-term access to GMP monepantel for NUZ-001
• Strengthens Neurizon's commercialization readiness and supply chain

Neurizon Therapeutics Limited has executed a strategic supply agreement with Elanco Animal Health, securing long-term access to GMP monepantel, the active ingredient in its lead drug NUZ-001. The agreement, which has an initial term of five years, provides Neurizon with scalable supply of monepantel for human health use, supporting its commercialization readiness. The agreement strengthens Neurizon's long-term manufacturing and supply framework, enhancing its commercialization strategy and operational scalability. The agreement also supports Neurizon's regulatory and CMC infrastructure, providing a supply of monepantel manufactured to human pharmaceutical specifications. Commercialization of NUZ-001 remains subject to successful clinical development, regulatory approval, and future commercial outcomes.